Skip to main content

Cohort Discovery

The UR CTSI now offers two different intuitive, user-friendly, HIPAA-compliant cohort discovery tools to help researchers determine study feasibility, obtain summary patient counts, and identify sites for potential partnerships in multi-site studies: TriNetX and the ACT Network. Both offer a myriad of benefits:

  • Real-time, open-access, HIPAA-compliant platforms that provide de-identified summary patient data
  • Use for study feasibility, which does not require RSRB approval
  • Online self-service with free training and closed captioning available




Query local EMR data and get secure, de-identified summary patient counts to determine the feasibility of your clinical studies.


ACT Network

 Validate study feasibility using aggregated EMR data from across the nation and identify potential partner sites for multi-site studies.



Find answers to frequently asked questions about navigating and using TriNetX and ACT, as well as troubleshooting issues.  

Submitting a request to CTSI Informatics to obtain lists of patients with specific conditions has been useful in identifying potential subjects for our Epilepsy clinical trials. Reviewing a targeted list of patients with a specific ICD-10 code(s) is more efficient than scanning the clinic schedule for possible subjects. The process to make the request using the REDCap form is easy; and recently the turnaround time has improved to just a few weeks. 

Cate Concannon, MPH,
Human Subject Research Coordinator, Neurology  

Which tool is right for you?

  • I need to identify the number of UR Medicine patients with a particular set of clinical criteria.
    • Use TriNetX
      • URMC has enough patients to satisfy my sample size criteria
      • URMC does not have enough patients to satisfy my sample size.
        • Consider running a multi-site clinical study.
          • Use ACT to identify potential collaborating sites with additional patients meeting study criteria.

Questions? Email